Form 4: Krystal Biotech CEO Krish Krishnan Executes Stock Sales Under 10b5-1 Trading Plan

Krystal Biotech's CEO, Krish Krishnan, and his spouse executed multiple sales of common stock on March 13, 2025, under pre-arranged 10b5-1 trading plans.

Summary

• Krish S. Krishnan, CEO of Krystal Biotech, Inc., reported the sale of common stock on March 13, 2025.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2024, which started on September 12, 2024, and will terminate on September 13, 2025.
• The plan contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share.
• Krishnan sold 24,991 shares directly at weighted average prices ranging from $175.8256 to $179.5735.
• His spouse, Suma M. Krishnan, also sold 24,992 shares under a similar 10b5-1 plan at weighted average prices ranging from $175.9724 to $179.5466.
• Following the transactions, Krishnan directly owns 1,533,056 shares and indirectly owns 140,000 shares through family trusts, while his spouse directly owns 1,463,711 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document reports routine stock sales under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's future prospects.

Future Outlook

The reporting person and their spouse will continue to sell shares under the 10b5-1 trading plan until September 13, 2025, subject to the plan's terms.

Industry Context

Insider sales are a common occurrence, especially when executed under pre-arranged trading plans like Rule 10b5-1, which allows insiders to sell shares without being accused of trading on non-public information. The market typically views these sales based on the context of the company's performance and the overall market conditions.

Comparison to Industry Standards

• It's common for executives at publicly traded companies, including those in the biotechnology sector like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, to utilize 10b5-1 trading plans for selling company stock.
• The volume and frequency of these sales are often compared to industry peers to assess whether the insider selling is routine or indicative of a change in sentiment regarding the company's prospects.
• For example, if executives at comparable companies are also selling shares under similar plans, it might be viewed as a normal liquidity event rather than a negative signal.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if the market interprets them negatively, potentially leading to a slight decrease in stock price.
• However, since the sales are pre-planned and disclosed, the impact is likely to be minimal.

Key Dates